Elens, Laure Langman, Loralie J. Hesselink, Dennis A. Bergan, Stein Moes, Dirk Jan A.R. Molinaro, Mariadelfina Venkataramanan, Raman Lemaitre, Florian
Published in
Therapeutic Drug Monitoring
COVID-19 is a novel infectious disease caused by the severe acute respiratory distress (SARS)-coronavirus-2 (SARS-CoV-2). Several therapeutic options are currently emerging but none with universal consensus or proven efficacy. Solid organ transplant recipients are perceived to be at increased risk of severe COVID-19 because of their immunosuppresse...
Bauer, Andrea C Franco, Rodrigo F Manfro, Roberto C
Published in
Current pharmaceutical design
Currently, kidney transplantation is the best treatment option for kidney failure for a majority of eligible patients. It is associated with a better quality of life and reduced mortality as compared to staying on dialysis. Many of the improvements in kidney transplant outcomes, observed in recent decades, are due to more efficient immunosuppressio...
Takai, Manabu Kameyama, Koji Toyota, Shohei Kamei, Shingo Yokoi, Shigeaki Ishihara, Satoshi Deguchi, Takashi
Published in
IJU case reports
A patient undergoing hemodialysis and being treated with everolimus for metastatic epithelioid angiomyolipoma has never been described in the literature, to our knowledge. A 53-year-old woman who had undergone trans-arterial embolization for epithelioid angiomyolipoma was referred with a chief complaint about right knee pain. Hemodialysis had been ...
Ibrahim, Sara M. Bakhashab, Sherin Ilyas, Asad M. Pushparaj, Peter N. Karim, Sajjad Khan, Jalaluddin A. Abuzenadah, Adel M. Chaudhary, Adeel G. Al-Qahtani, Muhammed H. Ahmed, Farid
...
Published in
Oncology Reports
Multidrug resistance (MDR) is a major reason for the failure of acute myeloid leukemia (AML) therapy. Agents that reverse MDR and sensitize AML cells to chemotherapy are of great clinical significance. The present study developed Adriamycin (Adr)-resistant cell lines, namely K562/Adr200 and K562/Adr500, which exhibited MDR. The upregulation of ATP-...
Nagyiványi, Krisztián Géczi, Lajos
Published in
Orvosi hetilap
Until the past decade, therapeutic options for unresectable and/or metastatic renal cell carcinoma were limited. Renal cell carcinoma is generally resistant to conventional chemotherapy, and only a small percentage of patients with renal cell carcinoma benefit from cytokine treatment. Since 2005, the advances in target-based therapy and immunothera...
Kälble, Florian Schaier, Matthias Schäfer, Sebastian Süsal, Caner Zeier, Martin Sommerer, Claudia Morath, Christian
Published in
Expert opinion on pharmacotherapy
The introduction of calcineurin inhibitors (CNI) has greatly improved graft survival in the past three decades. However, long-term graft survival is still limited due to chronic allograft injury and side-effects of immunosuppressive medication. Areas covered: The present overview gives an update on pharmacotherapeutic strategies after kidney transp...
Pal, Sumanta K Signorovitch, James E Li, Nanxin Zichlin, Miriam L Liu, Zhimei Ghate, Sameer R Perez, Jose Ricardo Vogelzang, Nicholas J
Published in
International journal of urology : official journal of the Japanese Urological Association
To assess real-world treatment patterns of targeted therapies after failure of first-line tyrosine kinase inhibitors in patients with advanced renal cell carcinoma. A large, retrospective review of medical charts of patients with advanced renal cell carcinoma in the USA was carried out. Descriptive statistics were used to summarize physicians' and ...
Chandrika, Goparaju Natesh, Kumar Ranade, Deepak Chugh, Ashish Shastry, Padma
Published in
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling pathway is crucial for tumor survival, proliferation, and progression, making it an attractive target for therapeutic intervention. In glioblastoma, activated mammalian target of rapamycin promotes invasive phenotype and correlates with poor patient survival. A wide range...
Howard, Stephanie A Rosenthal, Michael H Jagannathan, Jyothi P Krajewski, Katherine M Shinagare, Atul B Ramaiya, Nikhil H Tirumani, Sree Harsha
Published in
AJR. American journal of roentgenology
A substantial number of molecular targeted therapies act on nonantiangiogenic pathways. Familiarity with these drugs, their personalized tumor response criteria, and class- and drug-specific toxicities will help radiologists to be an integral part of the multi-disciplinary oncology team.
Gadducci, Angiolo Guerrieri, Maria Elena
Published in
Expert opinion on pharmacotherapy
DOX alone, gemcitabine alone, DOX + dacarbazine and gemcitabine + docetaxel may be treatment options for first-line and second-line therapies. However, the clinical benefit of the combination chemotherapy versus single-agent chemotherapy is still debated. Trabectedin is a promising agent for recurrent uterine LMS, able to obtain a prolonged disease...
